[{"id":"a368028e-686f-48d5-a817-2e4343d80bdf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04712877","created_at":"2021-01-19T20:52:47.325Z","updated_at":"2024-07-02T16:35:37.428Z","phase":"","brief_title":"Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers","source_id_and_acronym":"NCT04712877","lead_sponsor":"Lung Cancer Mutation Consortium","biomarkers":" EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation","tags":["EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 06/15/2022","start_date":" 06/15/2022","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2023-09-12"},{"id":"9e159383-2e08-450b-825f-55bca2d5ef97","acronym":"METROS","url":"https://clinicaltrials.gov/study/NCT02499614","created_at":"2021-01-18T12:03:34.728Z","updated_at":"2024-07-02T16:37:16.884Z","phase":"Phase 2","brief_title":"Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)","source_id_and_acronym":"NCT02499614 - METROS","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" MET • ROS1","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • ROS1 positive • MET mutation • MET amplification + MET Exon 14 mutation","tags":["MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • ROS1 positive • MET mutation • MET amplification + MET Exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 80","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-10-25"}]